- |||||||||| 8MW0511 / Mabwell (Shanghai) Biosci
Trial completion, Enrollment change, Trial completion date: Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF (clinicaltrials.gov) - Dec 2, 2022
P2/3, N=586, Completed,
As a novel, long-acting rhG-CSF modified with HSA, MW05 can effectively shorten DSN induced by chemotherapy and may reduce the incidence of FN and severe neutropenia. Recruiting --> Completed | N=348 --> 586 | Trial completion date: Sep 2023 --> Nov 2022
- |||||||||| MW05 / Mabwell (Shanghai) Biosci
Journal: Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. (Pubmed Central) - Aug 8, 2021
MW06 alone and the cocktail show good effects in preventing escape mutations, including a series of variants of concern, B.1.1.7, P.1, B.1.351, and B.1.617.1. These findings suggest that MW06 recognizes a conserved epitope on SARS-CoV-2, which provides insights for the development of a universal antibody-based therapy against SARS-related coronavirus and emerging variant strains, and may be an effective anti-SARS-CoV-2 agent.
- |||||||||| 8MW0511 / Mabwell (Shanghai) Biosci
Enrollment open: Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF (clinicaltrials.gov) - Dec 4, 2020
P2/3, N=348, Recruiting,
These findings suggest that MW06 recognizes a conserved epitope on SARS-CoV-2, which provides insights for the development of a universal antibody-based therapy against SARS-related coronavirus and emerging variant strains, and may be an effective anti-SARS-CoV-2 agent. Not yet recruiting --> Recruiting
|
